Literature DB >> 28561238

Sensitive LC-MS/MS Method for the Simultaneous Determination of Bendamustine and its Active Metabolite, γ-Hydroxybendamustine in Small Volume Mice and Dog Plasma and its Application to a Pharmacokinetic Study in Mice and Dogs.

Devaraj V Chandrashekar1, Ponnayyan S Suresh1, Rajnish Kumar1, Ravi Kanth Bhamidipati1, Ramesh Mullangi1, Wolfgang Richter2, Nuggehally R Srinivas3.   

Abstract

A highly sensitive, specific and rapid LC-ESI-MS/MS method has been developed and validated for the simultaneous quantification of bendamustine (BM) and γ-hydroxybendamustine (HBM) in small volume (20 µL) mice and dog plasma using phenacetin as an internal standard (IS) as per regulatory guidelines. Both the analytes and IS were extracted from mice and dog plasma using a liquid-liquid extraction method. Chromatography was achieved on Atlantis dC18 column using an isocratic mobile phase (0.2% formic acid:acetonitrile, 25:75) at a flow rate of 0.40 mL/min. The total chromatographic run time was 3.0 min and the elution of BM, HBM and IS occurred at ~1.2, 1.2 and 2.0 min, respectively. A linear response function was established 0.11-518 ng/mL for both the analytes in mice and dog plasma. The intra- and inter-day accuracy and precisions were in the range of 3.46-12.9 and 3.63-8.23%; 1.15-9.00 and 7.86-9.49% for BM and HBM, respectively in mice plasma and 2.15-6.49 and 1.73-13.1%; 4.35-13.9 and 4.33-10.5% for BM and HBM, respectively in dog plasma. This novel method has been applied to a pharmacokinetic study in mice and dogs. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28561238     DOI: 10.1055/s-0043-108124

Source DB:  PubMed          Journal:  Drug Res (Stuttg)        ISSN: 2194-9379


  4 in total

1.  Bendamustine with Total Body Irradiation Limits Murine Graft-versus-Host Disease in Part Through Effects on Myeloid-Derived Suppressor Cells.

Authors:  Jessica Stokes; Emely A Hoffman; Megan S Molina; Jelena Eremija; Nicolas Larmonier; Yi Zeng; Emmanuel Katsanis
Journal:  Biol Blood Marrow Transplant       Date:  2018-10-13       Impact factor: 5.742

2.  The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.

Authors:  Claudio Festuccia; Andrea Mancini; Alessandro Colapietro; Giovanni Luca Gravina; Flora Vitale; Francesco Marampon; Simona Delle Monache; Simona Pompili; Loredana Cristiano; Antonella Vetuschi; Vincenzo Tombolini; Yi Chen; Thomas Mehrling
Journal:  J Hematol Oncol       Date:  2018-02-27       Impact factor: 17.388

3.  Bendamustine Conditioning Skews Murine Host DCs Toward Pre-cDC1s and Reduces GvHD Independently of Batf3.

Authors:  Megan S Molina; Jessica Stokes; Emely A Hoffman; Jelena Eremija; Yi Zeng; Richard J Simpson; Emmanuel Katsanis
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

4.  Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia.

Authors:  Jessica Stokes; Emely A Hoffman; Megan S Molina; Nicole Kummet; Richard J Simpson; Yi Zeng; Emmanuel Katsanis
Journal:  Oncoimmunology       Date:  2020-04-30       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.